“My healthcare team and my Interconnect Care Coordinator helped me secure all the required paperwork to start OCALIVA.”
Rosalía, a person living with primary biliary cholangitis (PBC)
Interconnect® provides support for those with commercial insurance.
Interconnect is dedicated to helping you get access to OCALIVA® (obeticholic acid). You may be able to pay as little as $0 for your OCALIVA prescription.*
Whether you have commercial insurance, Medicare/Medicaid, or are uninsured, a Care Coordinator at Interconnect can help you find the most affordable way to get OCALIVA.
If you are currently commercially insured
Your Care Coordinator can enroll you in the copay program and determine if you are eligible to pay as little as $0 per month or to receive an introductory supply of OCALIVA at little to no cost.
If you have Medicare or Medicaid
If applicable, your Care Coordinator can identify independent financial assistance that can help cover the cost of treatment.
If you have no insurance or limited insurance
You may be able to receive OCALIVA at little to no cost. Your Care Coordinator can help you find out if you’re eligible.
View full terms and conditions >
You may be able to get your monthly OCALIVA prescription for as little as $0.*
Call your Care Coordinator at Interconnect today for more information at 1‑844‑622‑4278
Rosalía, a person living with primary biliary cholangitis (PBC)
Sign up for helpful tips, tools, and other materials to learn more about PBC and OCALIVA.
OCALIVA is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well enough to UDCA, or alone for adults who cannot tolerate UDCA. It is not known if taking OCALIVA will improve your chance of survival or improve your symptoms of PBC. It is not known if OCALIVA is safe and effective in children.
OCALIVA may cause serious side effects including:
Worsening of liver problems or liver failure, in some cases leading to liver transplant or death, has happened in people with primary biliary cholangitis (PBC) with liver cirrhosis when taking OCALIVA.
Before you start OCALIVA, and during your treatment with OCALIVA, your healthcare provider will do tests to check your liver. These tests will help your healthcare provider decide if it is safe for you to start taking OCALIVA and safe for you to continue taking OCALIVA.
Tell your healthcare provider right away if you have any of the following symptoms of worsening liver problems during treatment with OCALIVA:
Tell your healthcare provider right away if you have any of the following symptoms during treatment with OCALIVA and they are severe or do not go away:
Do not take OCALIVA if you:
OCALIVA may cause serious side effects, including:
The most common side effects of OCALIVA include: tiredness; stomach pain and discomfort; rash; joint pain; mouth and throat pain; dizziness; constipation; swelling in your hands, ankles, or feet; fast or irregular heartbeat; fever; changes in how your thyroid gland works; dryness, irritation, redness, crusting or drainage of the skin (eczema).
These are not all the possible side effects of OCALIVA. Call your doctor for medical advice about side effects.
Before taking OCALIVA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over‑the‑counter medicines, vitamins, and herbal supplements. OCALIVA can affect the way certain medicines work. Certain other medicines may affect the way OCALIVA works.
The risk information provided here is not complete. To learn more, please talk to your healthcare provider.
Please click here for Full Prescribing Information and Medication Guide for OCALIVA.
Available by prescription only.
To report negative side effects of OCALIVA, please contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or you may report to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
OCALIVA® (obeticholic acid) is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well enough to UDCA, or alone for adults who cannot tolerate UDCA. It is not known if taking OCALIVA will improve your chance of survival or improve your symptoms of PBC. It is not known if OCALIVA is safe and effective in children.
Worsening of liver problems or liver failure, in some cases leading to liver transplant or death, has happened in people with primary biliary cholangitis (PBC) with liver cirrhosis when taking OCALIVA.